BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord 2020;76:63-71. [PMID: 32461054 DOI: 10.1016/j.parkreldis.2020.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. Nutrients 2022;14:380. [PMID: 35057561 DOI: 10.3390/nu14020380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Zheng SY, Li HX, Xu RC, Miao WT, Dai MY, Ding ST, Liu HD. Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res Rev 2021;69:101347. [PMID: 33905953 DOI: 10.1016/j.arr.2021.101347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
3 Menozzi E, Macnaughtan J, Schapira AHV. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med 2021;53:611-25. [PMID: 33860738 DOI: 10.1080/07853890.2021.1890330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022. [PMID: 35750883 DOI: 10.1038/s41582-022-00681-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lipp MM, Hickey AJ, Langer R, LeWitt PA. A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease. Expert Opin Drug Deliv 2021;:1-11. [PMID: 34311641 DOI: 10.1080/17425247.2021.1960820] [Reference Citation Analysis]
6 Camilleri M. Gastrointestinal motility disorders in neurologic disease. J Clin Invest 2021;131:143771. [PMID: 33586685 DOI: 10.1172/JCI143771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med 2021;133:721-7. [PMID: 34082655 DOI: 10.1080/00325481.2021.1936087] [Reference Citation Analysis]
8 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs. [DOI: 10.1007/s40265-021-01664-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Soliman H, Coffin B, Gourcerol G. Gastroparesis in Parkinson Disease: Pathophysiology, and Clinical Management. Brain Sci 2021;11:831. [PMID: 34201699 DOI: 10.3390/brainsci11070831] [Reference Citation Analysis]
10 Lenka A, Di Maria G, Lamotte G, Bahroo L, Jankovic J. Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother 2022. [PMID: 35710101 DOI: 10.1080/14737175.2022.2091436] [Reference Citation Analysis]
11 Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Chaudhari VS, Jalundhwala YJ, Bao Y, Kukreja P, Isaacson SH. Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses. Neurol Ther 2022. [PMID: 35192177 DOI: 10.1007/s40120-022-00332-0] [Reference Citation Analysis]
12 Chung KA, Pfeiffer RF. Gastrointestinal dysfunction in the synucleinopathies. Clin Auton Res 2021;31:77-99. [PMID: 33247399 DOI: 10.1007/s10286-020-00745-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]